Finance
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
Published by Global Banking & Finance Review®
Posted on March 2, 2026
1 min readLast updated: March 2, 2026
Quick Summary
British medtech firm Smith & Nephew reported a 15.5% surge in annual trading profit to $1.21 billion for the year ended December 31, 2025, driven by its ongoing turnaround plan delivering cost savings and broad-based growth across its divisions.
UK medical products maker Smith & Nephew expects 8% profit boost in 2026
Smith & Nephew’s 2026 Profit Forecast and Strategic Initiatives
Profit Growth Outlook
March 2 (Reuters) - Medical products maker Smith & Nephew forecast its 2026 trading profit to grow around 8% organically, with revenue leverage and cost cuts offsetting pressures from inventory revaluation, tariffs, and a challenging Chinese market.
Turnaround and Division Performance
Orthopaedic Division Revamp
The British company finished a three‑year turnaround that revamped its orthopaedic division, cut costs, and lifted growth in its wound management and sports medicine units, following margin pressures from inflation and supply‑chain disruptions.
Wound Management and Sports Medicine Growth
Smith & Nephew also plans to further simplify its portfolio and reduce inventory by around $500 million under a new strategy, it said in December, while investing in higher-growth areas such as sports medicine.
Financial Performance
2025 Trading Profit Results
Year-on-Year Growth and Market Expectations
The company, which makes orthopaedic implants, wound dressings, and other surgical aids, reported a trading profit of $1.21 billion for the year ended December 2025, up 15.5% year-on-year, and in line with market expectations.
Reporting Credits
(Reporting by Yamini Kalia in Bengaluru; Editing by Rashmi Aich)
Key Takeaways
- •Trading profit rose to $1.21 billion, up from $1.05 billion, as the company’s 12‑Point Plan continued to yield operational efficiencies and margin expansion (2024 profit was $1.05 billion) (tradingview.com).
- •Momentum from product innovation and recovery in U.S. orthopaedics offset persistent weakness in China, where pricing pressures and VBP policies remain a drag (smith-nephew.com).
- •Smith & Nephew is targeting further margin gains in 2025, expecting full‑year trading profit margin to rise to 19–20%, supported by continued cost discipline and improved revenue growth (smith-nephew.com)
References
Frequently Asked Questions about UK medical products maker Smith & Nephew's annual profit jumps 15.5%
1What was Smith & Nephew's annual profit for 2025?
Smith & Nephew reported a trading profit of $1.21 billion for the year ended December 2025.
2How much did Smith & Nephew's annual profit increase compared to last year?
The company's annual profit increased by 15.5%, rising from $1.05 billion last year to $1.21 billion in 2025.
3What factors contributed to Smith & Nephew's profit growth?
The profit growth was driven by successful turnaround plans, cost savings, and boosted growth across the company's divisions.
4Who reported Smith & Nephew's financial results?
The financial results were reported by Yamini Kalia in Bengaluru and edited by Rashmi Aich.
